Who
Michael Schmertzler
Director
Company insider
Files Form 4 as: Director and 10% owner, PTC Therapeutics; Director and 10% owner, Hamilton Lane; Director and 10% owner, Cytokinetics.
In numbers
- Trades disclosed
- 164
- Buys
- 5
- Sells
- 20
- Bought
- $13.9M
- Sold
- $16.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 25 May 2006
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $126K2,118 at $59.52 | filing |
| 14 Oct 2026filed 16 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K382 at $60.14 | filing |
| 7 Oct 2026filed 9 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $155K2,447 at $63.38 | filing |
| 7 Oct 2026filed 9 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,38953 at $63.95 | filing |
| 17 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $653K9,624 at $67.83 | filing |
| 17 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K376 at $68.45 | filing |
| 17 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $653K9,624 at $67.83 | filing |
| 17 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K376 at $68.45 | filing |
| 16 Sep 2026filed 18 Sep 2026 | HLNE Hamilton LaneCapital Markets & Asset Management | SEC FORM 4 Code A | —977 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | HLNE Hamilton LaneCapital Markets & Asset Management | SEC FORM 4 Code A | —977 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $199K2,994 at $66.58 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $472K7,006 at $67.35 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $199K2,994 at $66.58 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $472K7,006 at $67.35 | filing |
| 10 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $673K10,000 at $67.34 | filing |
| 10 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $673K10,000 at $67.34 | filing |
| 9 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $639K9,428 at $67.79 | filing |
| 9 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $39K572 at $68.67 | filing |
| 9 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $639K9,428 at $67.79 | filing |
| 9 Sep 2026filed 11 Sep 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $39K572 at $68.67 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company Stocktickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 10,000 Shares of Stockthemarketsdaily.com · 12 Sep 2026PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026
2 headlines in the last 90 days name Michael Schmertzler; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.